OMIDRIA SETS THE STAGE FOR YOUR CATARACT SURGERY SUCCESS^1-3

FDA-approved OMIDRIA: Count on performance that stays ahead of the unexpected

Learn more about OMIDRIA

EFFECTIVELY MAINTAINS pupil dilation

and requires less use of PEDs^1,4-8

Review the data

REDUCES COMPLICATIONS

such as IFIS, CME, and breakthrough iritis^2,3

See the benefits

IMPROVED PATIENT EXPERIENCE

with less pain, greater visual acuity, and fewer drops^1,3,4

See the results

OMIDRIA helps provide access and support to patients

Dedicated access to comprehensive reimbursement programs for your cataract procedures.

Access & Support

Download OMIDRIAssure® flashcard

Schedule an in-service with your OMIDRIA Field Reimbursement Manager by emailing omidriafrms@rayner.com or by calling 1-844-RAYNER1 (1-844-729-6371).

CME=cystoid macular edema; IFIS=intraoperative floppy iris syndrome; PEDs=pupil expansion devices.

REFERENCES: 1. OMIDRIA [package insert]. Bellevue, WA: Rayner Surgical Inc. 2023. 2. Silverstein SM, Rana VK, Stephens R, et al. Effect of phenylephrine 1.0%–ketorolac 0.3% injection on tamsulosin-associated intraoperative floppy-iris syndrome. J Cataract Refract Surg. 2018;44(9):1103-1108. 3. Visco DM, Bedi R. Effect of intracameral phenylephrine 1.0%–ketorolac 0.3% on postoperative cystoid macular edema, iritis, pain, and photophobia after cataract surgery. J Cataract Refract Surg. 2020;46(6):867-872. 4. Rosenberg ED, Nattis AS, Alevi D, et al. Visual outcomes, efficacy, and surgical complications associated with intracameral phenylephrine 1.0%/ketorolac 0.3% administered during cataract surgery. Clin Ophthalmol. 2018;12:21-28. 5. Al-Hashimi S, Donaldson K, Davidson R, et al. Medical and surgical management of the small pupil during cataract surgery. J Cataract Refract Surg. 2018;44(8):1032-1041. 6. Bucci FA Jr, Michalek B, Fluet AT. Comparison of the frequency of use of a pupil expansion device with and without an intracameral phenylephrine and ketorolac injection 1%/0.3% at the time of routine cataract surgery. Clin Ophthalmol. 2017;11:1039-1043. 7. Walter K, Delwadia N, Coben J. Continuous intracameral phenylephrine–ketorolac irrigation for miosis prevention in femtosecond laser–assisted cataract surgery: reduction in surgical time and iris manipulation. J Cataract Refract Surg. 2019;45(4):465-469. 8. Visco D. Effect of phenylephrine/ketorolac on iris fixation ring use and surgical times in patients at risk of intraoperative miosis. Clin Ophthalmol. 2018;12:301-305.

INDICATIONS AND USAGE

OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

IMPORTANT SAFETY INFORMATION

OMIDRIA must be added to irrigating solution prior to intraocular use.

OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.

Systemic exposure to phenylephrine may cause elevations in blood pressure.

Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.

The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

Please see the Full Prescribing Information for OMIDRIA.

You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.